Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results

MT Newswires Live

2024/12/26

Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced "encouraging" safety and efficacy results in patients with chronic hepatitis B virus.

The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.

The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.

The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.

Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.

Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2494868612"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494868612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494868612?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-26 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494868612","market":"sh","top_or_hot":-1,"title":"Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results","media":"MT Newswires Live","content":"<html><body><p> Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.</p><p>The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.</p><p>The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.</p><p>The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.</p><p>Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.</p><p>Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Says Antiviral Drug Shows 'Encouraging' Phase 1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-26 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.</p><p>The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.</p><p>The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.</p><p>The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.</p><p>Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.</p><p>Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2494868612","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494868612","pubTimestamp":1735220259,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Assembly Biosciences  said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.Following completion of the phase 1b study, Gilead Sciences  has the right to opt in to further development and commercialization of the drug, the company said.Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4566":"资本集团","LU0058720904.USD":"联博国际健康护理基金A","BK4578":"CAR-T","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4583":"猴痘概念","GILD":"吉利德科学","ASMB":"Assembly Biosciences Inc.","BK4532":"文艺复兴科技持仓","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC"},"translate_title":"Assembly Biosciences表示抗病毒药物显示出“令人鼓舞”的第一阶段结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1,"GILD":0.9},"content_text":"Assembly Biosciences (ASMB) said Thursday that an ongoing phase 1b study of its investigational antiviral drug ABI-4334 produced \"encouraging\" safety and efficacy results in patients with chronic hepatitis B virus.The company cited improvements in trial-defined measures of antiviral activity in a study cohort that received an oral, once-daily 150 mg dose of ABI-4334 over 28 days.The study also showed the drug was well-tolerated and had a favorable safety profile, the company said.The biotechnology firm said it is now enrolling patients for a 400 mg daily trial cohort, with data expected to be released in H1 2025.Following completion of the phase 1b study, Gilead Sciences (GILD) has the right to opt in to further development and commercialization of the drug, the company said.Assembly Bio shares were up more than 1.5% in Thursday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}